| 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因 公告全部或任何部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 | | | --- | --- | | 股票發行人現金股息公告 | | | 發行人名稱 | 上海醫藥集團股份有限公司 | | 股份代號 | 02607 | | 多櫃檯股份代號及貨幣 | 不適用 | | 相關股份代號及名稱 | 不適用 | | 公告標題 | 截至2024年12月31日止年度之末期股息 (更新） | | 公告日期 | 2025年5月29日 | | 公告狀態 | 更新公告 | | 更新/撤回理由 | 更新股東批准日期 | | 股息信息 | | | 股息類型 | 末期 | | 股息性質 | 普通股息 | | 財政年末 | 2024年12月31日 | | 宣派股息的報告期末 | 2024年12月31日 | | 宣派股息 | 每 10 股 2.9 RMB | | 股東批准日期 | 2025年6月26日 | | 香港過戶登記處相關信息 | | | 派息金額及公司預設派發貨幣 | 有待公佈 | | 匯率 ...

股東名稱： 02607 2. 請填上以 閣下名稱登記的股份數目。 H股股東出席 股東週年大會回條 3. 就公司H股持有者而言，此填妥及經簽署的回條須於2025年6月16日或之前透過專人或郵遞送達公司的 H股證券登記處MUFG Corporate Markets Pty Limited，地址為香港中環皇后大道中28號中匯大廈16樓 1601室。公司H股持有人須確保於2025年6月20日16:30前將所有過戶文件連同有關股票送交公司的H股 證券登記處MUFG Corporate Markets Pty Limited（地址為香港中環皇后大道中28號中匯大廈16樓1601 室），以符合資格出席股東週年大會（或其任何續會）並於會上投票。 致：上海醫藥集團股份有限公司（「公司」） 股東名稱及登記地址 （附註1） ： 持股數目 （附註2） : 股H股 本人╱吾等擬親自出席或委任代表出席於2025年6月26日13:00於中國上海市徐匯區楓林路450 號楓林國際大廈二期六樓裙樓601會議室舉行的公司股東週年大會（或其任何續會）。 股東簽署： 日期：2025年 月 日 Shanghai Pharmaceuticals Hold ...

股東週年大會通知 香港交易及結算所有限公司及香港聯合交易所有限公司對本通告之內容概不負責，對其 準確性或完整性亦不發表任何聲明，並明確表示，概不對因本通告全部或任何部分內容 而產生或因依賴該等內容而引致之任何損失承擔任何責任。 Shanghai Pharmaceuticals Holding Co., Ltd. * 02607 茲通知上海醫藥集團股份有限公司（「本公司」）謹訂於2025年6月26日13:00於中國上海市徐 匯區楓林路450號楓林國際大廈二期六樓裙樓601會議室舉行股東週年大會，以審議及批 准下列事項： 普通決議 特別決議 - 1 - (1) 2024年度報告 (2) 2024年度董事會工作報告 (3) 2024年度監事會工作報告 (4) 2024年度財務決算報告及2025年度財務預算報告 (5) 2024年度利潤分配預案 (6) 關於續聘會計師事務所的議案 (7) 關於2025年度對外擔保計劃的議案 (8) 關於發行債務融資產品的議案 (9) 關於公司符合發行公司債券條件的議案 * 僅供識別 (10) 關於發行公司債券的議案 (11) 關於公司一般性授權的議案 承董事會命 上海醫藥集團股份有限 ...

此乃要件 請即處理 閣下如對本通函任何方面或應採取的行動有任何疑問，應諮詢 閣下的股票經紀或其他註冊證 券商、銀行經理、律師、專業會計師或其他專業顧問。 閣下如已將名下的上海醫藥集團股份有限公司的股份全部售出或轉讓，應立即將本通函及隨附 的代表委任表格及回條交予買主或承讓人，或經手買賣或轉讓的銀行、股票經紀或其他代理 商，以便轉交買主或承讓人。 香港交易及結算所有限公司及香港聯合交易所有限公司對本通函的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不會就本通函全部或任何部分內容而產生或因依賴 該等內容而引致的任何損失承擔任何責任。 Shanghai Pharmaceuticals Holding Co., Ltd. * 有關本公司股東週年大會的相關會議通知、適用代表委任表格及回條隨本通函附奉。 就H股持有人而言，無論 閣下能否出席股東週年大會，務請細閱股東週年大會通知。倘 閣 下擬委派代表出席股東週年大會，請按照隨附代表委任表格上印列的指示填妥及交回代表委任 表格。填妥及交回代表委任表格後， 閣下仍可親自出席股東週年大會（或其任何續會），並於 會上投票。 就H股持有人而言，倘 閣下擬親自或委 ...

Summary of M&A Activity in Q1 2025 Core Insights - The M&A market in Q1 2025 saw a total of 534 transactions with a combined value of 2371.86 billion RMB, maintaining a steady volume compared to the same period last year [2][21] - The most active sectors for M&A transactions included traditional industries, smart manufacturing, and energy and power [23][25] Group 1: Transaction Volume and Value - In Q1 2025, there were 421 newly disclosed M&A transactions valued at 1040.28 billion RMB, with 173 completed transactions worth 1282.89 billion RMB [21][23] - Traditional industries led the transaction volume with 94 deals (17.60%), followed by smart manufacturing with 71 deals (13.30%) and energy and power with 48 deals (8.99%) [23][25] Group 2: Sector Analysis - The largest disclosed transaction value was in traditional industries, reaching 190.52 billion RMB, followed by cultural entertainment at 156.09 billion RMB and e-commerce at 119.67 billion RMB [4][25] - Within traditional industries, the most active sub-sectors included traditional manufacturing (35 deals), construction (15 deals), traditional energy (7 deals), and real estate and home furnishings (5 deals) [3][25] Group 3: Regional Distribution - M&A activity was predominantly concentrated in the eastern coastal regions of China, with Guangdong leading with 60 transactions, followed by Jiangsu (49 transactions) and Shanghai (43 transactions) [5][27] - In terms of transaction value, Guangdong also topped the list with 225.39 billion RMB, followed closely by Shanghai at 223.26 billion RMB and Jiangsu at 112.65 billion RMB [5][27] Group 4: Transaction Size and Company Age - The majority of transactions were small, with 70 deals (26.02%) valued at under 10 million RMB, followed by 36 deals in the 200 million to 500 million RMB range [6][29] - Companies established between 5 to 10 years accounted for 25.90% of the M&A targets, with 109 such companies involved [31] Group 5: Public Company Acquisitions - A total of 22 publicly listed companies were acquired in Q1 2025, indicating a shift in control for these firms [8][32] - Notable transactions included two "A and A" deals and one "A and H" deal, highlighting the ongoing consolidation in the market [8][32] Group 6: Acquisition Methods and Buyer Intentions - Agreement-based acquisitions remained the dominant method, accounting for 78.93% of transactions, followed by share issuance for asset purchases at 8.38% [10][34] - The primary motive for acquisitions was horizontal integration, representing 63.49% of the transactions, aimed at market expansion and long-term development [12][36] Group 7: Institutional Participation and Exits - Institutions participated in 58 acquisition transactions, primarily in sectors like healthcare, energy, and automotive [14][38] - Notable exits included 47 transactions involving institutional investors, with significant activity in energy and automotive sectors [16][40]

Group 1 - A total of 26 companies were investigated by institutions on May 26, with 20 companies specifically targeted by funds [1] - The most popular company among funds was Cankin Technology, which had 13 participating funds, followed by Greebo and Hars, each with 12 funds [1] - The companies investigated belong to various sectors, including electronics, machinery, basic chemicals, and pharmaceutical biology, with three stocks from each of these sectors being highlighted [1] Group 2 - Among the companies investigated, four had a total market capitalization exceeding 50 billion yuan, with BOE Technology Group being one of them, while ten companies had a market cap below 10 billion yuan [1] - In terms of market performance, eight stocks among the investigated companies saw an increase in the last five days, with Kailer Co., Zhongsheng Pharmaceutical, and Zhongchumei leading with increases of 21.62%, 7.52%, and 5.76% respectively [1] - Conversely, twelve stocks experienced declines, with Jiangnan Yifan, Tangyuan Electric, and Greebo showing the largest drops of 5.68%, 4.34%, and 3.89% respectively [1] Group 3 - The funds that participated in the investigations included significant net inflows, with Zhongsheng Pharmaceutical receiving a net inflow of 122 million yuan, the highest among the stocks [2] - Other companies with notable net inflows included Haida Group and Kailer Co., with net inflows of 36.68 million yuan and 11.77 million yuan respectively [2] - The table of companies investigated includes various details such as stock codes, latest closing prices, five-day price changes, and industry classifications [2][3]

Core Viewpoint - The China Securities Index for Food and Major Consumer Goods Retail has shown a decline in performance over various time frames, indicating potential challenges in the sector [1][2]. Group 1: Index Performance - The China Securities Index for Food and Major Consumer Goods Retail is currently at 9719.75 points, having decreased by 0.13% over the past month, 2.88% over the past three months, and 4.47% year-to-date [1]. - The index is based on a sample of listed companies in the food and drug retail sector, reflecting the overall performance of these securities [1]. Group 2: Index Composition - The top ten weighted companies in the index include Yonghui Supermarket (6.96%), Digital China (6.48%), Shanghai Pharmaceuticals (6.14%), Yifeng Pharmacy (4.97%), and others, indicating a concentration in a few key players [1]. - The index is primarily composed of companies listed on the Shanghai Stock Exchange (55.91%) and Shenzhen Stock Exchange (44.09%) [1]. Group 3: Industry Breakdown - The industry composition of the index shows that pharmaceutical commerce accounts for 48.65%, specialized retail for 19.84%, department stores for 16.99%, and supermarkets and convenience stores for 14.52% [2]. - The index samples are adjusted biannually, with changes implemented on the next trading day following the second Friday of June and December [2].

Group 1 - Huiyu Pharmaceutical's subsidiary received drug registration certificate for Carboxymethyl Sodium Injection, which is used for treating bleeding diseases in various medical fields [1] - Baihe Co., Ltd. announced a plan for a director to reduce holdings by up to 424,000 shares, representing 0.6625% of the total share capital [1] - Kingood Co., Ltd. received a notification from a global leading automaker for a wheel project, expected to start mass production in 2026 with a lifecycle of 10 years [1][2] Group 2 - Wanhua Chemical plans to repurchase shares worth between 300 million and 500 million yuan, with a maximum repurchase price of 99.36 yuan per share [2] - Warner Pharmaceutical's subsidiary received approval for Acetylcysteine raw material drug, primarily used for treating respiratory diseases [3] - ST Mingcheng plans to publicly transfer 45% equity of its subsidiary, aiming to optimize asset structure [4] Group 3 - Qixia Construction announced a plan to reduce up to 31.5 million shares, accounting for 3% of total share capital [5][6] - Zhejiang Rongtai intends to invest 20 million yuan to establish a wholly-owned subsidiary focused on intelligent robotics [7] - Yuandong Biological received drug registration for Chloral Hydrate Enema, used for sedation and seizure control in children [9] Group 4 - Jiemai Technology's subsidiary signed a strategic cooperation agreement with a solid-state battery company to produce high-safety composite conductive materials [10] - Xianju Pharmaceutical received drug registration for Progesterone Soft Capsules, used for treating functional disorders due to luteal deficiency [11] - Lanhua Kecai's subsidiary reported a temporary production halt, with the resumption date yet to be determined [13] Group 5 - Sinopharm Modern's subsidiary received drug registration for Tocilizumab Tablets, used for treating rheumatoid arthritis and other conditions [15] - Shanghai Bank announced the resignation of its vice president due to organizational adjustments [17] - Shanghai Pharmaceutical's Ephedrine Injection passed the consistency evaluation for generic drugs [19] Group 6 - Rundu Co., Ltd. received drug registration for Amlodipine and Olmesartan Tablets, aimed at treating hypertension [21] - Zhong'an Technology announced that 61 million shares held by its controlling shareholder will be auctioned [23] - Shanghai Washba plans to purchase patent assets and establish two subsidiaries focused on hydrogen energy and solid-state battery technologies [25] Group 7 - Nuo Cheng Jianhua's new drug Tafasitamab received approval for treating relapsed/refractory diffuse large B-cell lymphoma [26] - Benli Technology plans to use up to 200 million yuan of idle funds for cash management and financial investments [28] - Taiji Co., Ltd. intends to use 60 million yuan of idle funds to purchase financial products [29] Group 8 - Haishi Co. announced that its innovative drug Anreke Fen Injection received drug registration for treating postoperative pain [32] - Yulong Co. will have its stock delisted on May 27, 2025, following a decision by the Shanghai Stock Exchange [36] - Weifu High-Tech plans to establish a joint venture with Shanghai Baolong Automotive Technology [38] Group 9 - Xichang Electric Power expects a net profit reduction of approximately 5.4 million yuan due to adjustments in the time-of-use electricity pricing mechanism [39] - Alter signed a contract worth 6.8 billion yen for the development and procurement of large truck EV kits [41] - Zhonglian Heavy Industry plans to acquire controlling stakes in its financing leasing subsidiary through public bidding [42] Group 10 - Sanyou Medical's executive plans to reduce holdings by up to 1.44% of the company's shares [43] - Hangyang Co. plans to establish a subsidiary for large modular cryogenic equipment manufacturing with an estimated investment of 557 million yuan [44] - FAW Fuwi received a notification for a dashboard project from a well-known new energy brand, with total sales expected to reach 1.06 billion yuan [45]

香港交易及結算所有限公司和香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因依賴 該等內容而引致的任何損失承擔任何責任。 （於中華人民共和國註冊成立的股份有限公司） （股份代碼：02607） 海外監管公告 本公告乃根據香港聯合交易所有限公司證券上市規則第 13.10B 條而作出。 茲載列上海醫藥集團股份有限公司（「本公司」）在上海證券交易所網站(http://www.sse.com.cn) 刊登的《上海醫藥集團股份有限公司關於重酒石酸去甲腎上腺素注射液通過仿製藥一致性評 價的公告》僅供參閱。 承董事會命 上海醫藥集團股份有限公司 楊秋華 董事長 中國上海，2025 年 5 月 22 日 於本公告日期，本公司的執行董事為楊秋華先生、沈波先生、李永忠先生及董明 先生；非執行董事為張文學先生；以及獨立非執行董事為顧朝陽先生、霍文遜先 生、王忠先生及萬鈞女士。 * 僅供識別 上 海 醫 藥 集 團 股 份 有 限 公 司 Shanghai Pharmaceuticals Holding Co., Ltd. * 药品名称：重酒石酸去 ...

证券代码：601607 证券简称：上海医药 公告编号：临2025-058 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 近日，上海医药集团股份有限公司（以下简称"上海医药"或"公司"）下 属上海禾丰制药有限公司（以下简称"上药禾丰"）的重酒石酸去甲肾上腺素注 射液（规格：1ml:2mg；以下简称"该药品"）收到国家药品监督管理局（以下 简称"国家药监局"）颁发的《药品补充申请批准通知书》（通知书编号： 2025B02097），该药品通过仿制药一致性评价。 一、该药品基本情况 药品名称：重酒石酸去甲肾上腺素注射液 剂型：注射剂 规格：1ml:2mg 注册分类：化学药品 申请人：上海禾丰制药有限公司 批准文号：国药准字 H31021177 审批结论：本品通过仿制药质量和疗效一致性评价 二、该药品相关的信息 重酒石酸去甲肾上腺素注射液主要用于某些急性低血压状态(例如铬细胞切 除术、交感神经切除术、脊髓灰质炎、脊髓麻醉、心肌梗死、败血症、输血和药 物反应)的血压控制。作为心脏骤停和严重低血压的辅助治疗手段。对血容量不 足导致的 ...